Nrx Pharmaceuticals, INC 8-K filings

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has signed a non-binding letter of intent to acquire its first interventional psychiatry clinics in Florida.

NRx Pharmaceuticals has completed the second tranche of its convertible note offering, raising an additional $5 million and issuing warrants for common stock.

NRx Pharmaceuticals' CEO Stephen Willard resigned, Jonathan Javitt was appointed Interim CEO, and shareholders approved key proposals including a share issuance and a reverse stock split authorization at the 2024 Annual Meeting.

NRx Pharmaceuticals is searching for a new CEO with commercial pharmaceutical and drug launch experience, as the company prepares for new drug applications for NRX-100 and NRX-101.

NRx Pharmaceuticals announced its second quarter 2024 financial results, highlighted by reduced net losses and secured funding to support New Drug Applications for NRX-100 and NRX-101.

NRx Pharmaceuticals has obtained up to $16 million in convertible debt financing to support its drug development programs and retire existing debt.

NRx Pharmaceuticals has received a notice from Nasdaq regarding its failure to maintain the minimum market value of listed securities, placing it at risk of delisting.

NRx Pharmaceuticals has terminated its agreement with Alvogen for the development of NRX-101 due to differing views on the scale of required clinical trials.

NRx Pharmaceuticals has appointed Dr. Dennis McBride, a veteran in neuroscience and medical technology, to its Board of Directors.

NRx Pharmaceuticals has closed the exercise of the underwriter's option to purchase additional shares, resulting in the sale of 91,050 shares at $3.30 per share.

NRx Pharmaceuticals announced positive clinical trial results for NRX-101 in bipolar depression, plans for two New Drug Application filings, and secured a term sheet for up to $30 million in debt financing.

NRx Pharmaceuticals is facing a default notice and lawsuit from Streeterville Capital related to a convertible note, while also announcing positive findings from a Phase 2b/3 clinical trial for NRX-101.

NRx Pharmaceuticals has successfully priced a public offering of common stock, raising approximately $2 million before expenses.

NRx Pharmaceuticals has increased the maximum aggregate offering price of its common stock under an existing agreement to $4.85 million.

NRx Pharmaceuticals announces a significant reduction in net loss and corporate overhead, along with advancements in clinical trials and a new partnership, positioning the company for potential revenue generation in 2024.

NRx Pharmaceuticals has announced a 1-for-10 reverse stock split of its common stock, effective April 1, 2024, to maintain its Nasdaq listing and attract institutional investors.

NRx Pharmaceuticals' shareholders have approved a proposal allowing the Board of Directors to implement a reverse stock split at their discretion within a specified range.

NRx Pharmaceuticals has closed the exercise of an underwriter option to purchase an additional 750,000 shares of common stock at $0.30 per share.

NRx Pharmaceuticals successfully priced a public offering of common stock, raising approximately $1.5 million to support working capital and general corporate needs.

NRx Pharmaceuticals has amended its convertible promissory note with Streeterville Capital, extending the maturity and adjusting payment terms to conserve cash for drug development.

NRx Pharmaceuticals has received a $5 million advance milestone payment from Alvogen and Lotus to fund the development of NRX-101 through the phase 2 meeting with the FDA.

NRx Pharmaceuticals has successfully transferred its stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective January 19, 2024.

NRx Pharmaceuticals has received an extension from Nasdaq to regain compliance with listing rules, contingent on transferring to the Nasdaq Capital Market and meeting minimum bid price requirements by April 16, 2024.